Biohaven (BHVN) vs Generate Biomedicines (GENB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Generate Biomedicines is the larger company by market cap ($1.85 billion vs $1.83 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BHVN | GENB |
|---|---|---|
| Share price | $12.14 | $14.40 |
| Market cap | $1.83B | $1.85B |
| 1-day change | +1.76% | +2.89% |
| YTD return | +5.67% | — |
| 1-year return | -22.23% | — |
| EPS (TTM) | $-4.56 | $-2.44 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-738.82M | — |
| 52-week high | $18.57 | $22.67 |
| 52-week low | $7.48 | $11.00 |
| Distance from 52-week high | -34.61% | -36.50% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +75.21% | +87.57% |
| Average volume | 2.62M | 1.05M |
| Shares outstanding | 151.04M | 128.35M |
| Employees | 274 | 312 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Biohaven
BHVN stock →Biohaven Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for immunology, neuroscience, and oncology therapeutic areas worldwide. It develops BHV-1300, which is in Phase 2 clinical trial to treat Graves' disease and rheumatoid arthritis; BHV-1400 that is in Phase 2 clinical trial for treating IgA nephropathy; BHV-1600, which is in Phase 1 clinical trial for the treatment of peripartum cardiomyopathy; BHV-8000 that is in Phase 3 clinical trial for treating Parkinson's disease; Opakalim, which is in Phase 3 clinical trial for the treatment of focal epilepsy; BHV-2100 that is in Phase 2 clinical trial for the treatment of pain disorders; and BHV-2000, which is in Phase 2 clinical trial for treating obesity.
Health Care · Biotechnology: Pharmaceutical Preparations · 274 employees
About Generate Biomedicines
GENB stock →Generate Biomedicines, Inc., engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics in the United States. It uses protein-based modalities for drug development.
Health Care · Biotechnology: Pharmaceutical Preparations · 312 employees
BHVN vs GENB FAQ
Which is bigger, Biohaven or Generate Biomedicines?
Generate Biomedicines (GENB) is larger, with a market capitalization of $1.85B compared with $1.83B for Biohaven (BHVN).
Are Biohaven and Generate Biomedicines in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.